Articles

Researchers at the USC Schaeffer Center have been studying the pharmaceutical distribution system since 2016; these comments about PBMs draw on that body of research.

After believing the pandemic would be under control by Memorial Day 2021, Schaeffer Center expert Geoffrey Joyce writes why he believes COVID is nowhere near under control.

Nonresident Senior Fellow Joe Grogan argues that the FDA approval process is slowing down drug innovation.

Populations underrepresented in clinical trials face worse health outcomes that will cost the U.S. trillions of dollars over the next three decades.

As of 2021, US health care expenditures exceed $3.8 trillion. It’s no secret that health care is nearly as wasteful in spending on value defects—behaviors that needlessly reduce quality, negatively impact the patient experience, or add to total costs of care—as it is in delivering clinical benefits.

USC Price is remembering Rocio Ribero, a research scientist who produced groundbreaking work in the Schaeffer Center for Health Policy and Economics.

Although big data is revolutionizing healthcare, its potential has been limited by underrepresentation of vulnerable populations, including marginalized racial and socioeconomic groups that are at higher risk for poor health outcomes.

In the long term, capping insulin payments at $35 a month is just shuffling the deck rather than changing the game of insulin costs.

To get past the allure of continued and often troublesome opioid use patterns, patients and doctors need a plan in hand before the first opioid is ever used.

Rosalie Liccardo Pacula presented findings at the U.N. Commission on Narcotic Drugs side event.